<DOC>
	<DOCNO>NCT01400074</DOCNO>
	<brief_summary>In study , efficacy nilotinib 400 mg BID compare imatinib 400 mg BID suboptimal molecular response patient . To determine study eligibility , suboptimal molecular response define patient achieve complete cytogenetic response ( CCyR ) achieve MMR , least 18 month treatment first line imatinib therapy minimum dose 400mg daily ( Baccarani 2006 ) .</brief_summary>
	<brief_title>Efficacy Nilotinib Versus Imatinib Ph+ CML Early CP Who Have Suboptimal Molecular Response Imatinib</brief_title>
	<detailed_description>Imatinib mesylate ( imatinib ) bind inactive conformation Bcr-Abl tyrosine kinase suppress Ph+ clone CML ( Giles et al , 2005 ) . It effective CML major advance therapy . With standard dose imatinib , MMR complete molecular response ( CMR ) rate 35 % 40 % 6 % 10 % respectively 12 month . These surrogate endpoint associate high long term survival rate ( Kantarjian et al , 2004 ) . For patient CCyR MMR ( define reduction Bcr-Abl transcript level least 3 log 12 month follow imatinib therapy ) , probability remain progression-free 100 percent 24 month , compare 95 % patient achieve CCyR MMR 85 % patient achieve CCyR ( P &lt; 0.001 ) ( Hughes et al , 2003/Druker et al , 2006 ) . With continued dos imatinib 400 mg/day , MMR 24 month 54 % ( IRIS SmPC data ) , however high dose imatinib 800 mg/day , MMR may 70 % . Higher dos imatinib improve CCyR rate 90 % patient fail prior IFN-alfa therapy previously untreated ( Cortes et al , 2005 ) . Higher dos expect yield high MMR rate 24 month ( Cortes et al , ASH 2004 poster ) . There also continue increase cumulative major/complete cytogenetic molecular response rate therapy , even 2 year ( Kantarjian 2004 ) . Nilotinib novel , oral tyrosine kinase inhibitor improve potency compare imatinib . In pre-clinical model imatinib-sensitive CML cell line , nilotinib 20-50 time potent imatinib , 3-7 time potent imatinib-resistant cell line . In Phase I dose-escalation trial [ Study CAMN107A2101 ] , 119 imatinib-resistant Ph+ CML ALL patient treat single oral dos nilotinib range 50-1200 mg daily 400 mg 600 mg give twice daily . Nilotinib produce high hematologic cytogenetic response rate 92 % 53 % , respectively ( CCyR 35 % ) , patient chronic phase CML , resistant imatinib . Nilotinib find acceptable tolerability profile ( Kantarjian et al , 2005 ) . Preliminary result ongoing Phase II study appear confirm efficacy safety profile nilotinib ( Kantarjian et al , 2006 ) . Achievement major molecular response important short-term goal CML therapy appear predict long-term event-free survival . This study design compare efficacy nilotinib 400 mg twice daily patient ' maximum tolerate dos imatinib ( optimally 800 mg/day ) produce major molecular response 12 month treatment individual previously major molecular remission . It also examine rate major molecular complete molecular response treatment arm , achievement endpoint may also prognostic significance .</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Male female patient ≥ 18 year age ECOG 0 , 1 , 2 Diagnosis Ph+ CML CP Patients suboptimal molecular response define : Patients must achieve CCyR 12 month must maintain CCyR study entry ( 0 % Ph+ chromosome ) . Cytogenetic confirmation Ph+ ( 9 ; 22 translocation ) require minimum 20 metaphase . FISH analysis accept . least 18 month 24 month ( ≥18 ≤24 month ) treatment imatinib first line therapy , dose 400 mg daily , without achieve MMR ( &lt; 0.1 % IS BcrAbl transcript RQ PCR ) . The following laboratory result must present : Total bilirubin &lt; 1.5 x ULN SGOT SGPT &lt; 2.5 x ULN Creatinine &lt; 1.5 x ULN Serum amylase lipase ≤ 1.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . Serum potassium , magnesium calcium ≥ LLN correctable supplement within normal limit prior first dose study medication . Ability provide write informed consent prior study related screening procedure perform . Late CP start imatinib 6 month diagnosis Prior accelerate phase blast phase CML Rare hereditary problem galactose intolerance , severe lactase deficiency glucose galactose malabsorption Hypersensitivity nilotinib excipients . Previously document T315I mutation . Intolerance imatinib 400 mg daily define inability maintain least 400 mg daily previous 3 month . Patients treat imatinib 400mg daily Achieved prior MMR CCyR imatinib lose response enter study . Previous treatment interferon tyrosine kinase inhibitor except imatinib ( however , allow hydroxyurea anagrelide initial imatinib start ) Impaired cardiac function Treatment inhibitor CYP3A4 medication well document prolong QT interval contraindicate Impaired gastrointestinal ( GI ) function GI disease History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) . Any malignancy clinically significant require active intervention . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , acute chronic liver disease , pancreatic , severe renal disease unrelated tumor , active uncontrolled infection ) . History significant congenital acquire bleed disorder unrelated cancer . Previous radiotherapy ≥ 25 % bone marrow . Major surgery within 4 week prior Day 1 study recover prior surgery . Use therapeutic coumarin derivative ( i.e . warfarin , acenocoumarol , phenprocoumon ) . Treatment investigational agent within 30 day Day 1 . History noncompliance medical regimen inability grant consent . Women pregnant , breast feeding , childbearing potential without negative serum urine pregnancy test baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>